HYDERABAD/BENGALURU (Reuters) -Sun Pharmaceutical, India's largest drugmaker by revenue, reported a bigger-than-expected ...

By Kashish Tandon and Rishika Sadam HYDERABAD/BENGALURU (Reuters) -Sun Pharmaceutical, India's largest drugmaker by revenue, ...

Sun Pharmaceutical ... US sales increasing just 0.7 per cent. Most of India's generic drugmakers derive a significant share of revenue from the United States, where lower drug prices due to stiff ...

“The film explores the timeless struggle between tradition and modernity – something that remains deeply relevant in India. Despite significant progress, we continue to grapple with entrenched ...

The Competition Commission of Pakistan has been awarded three-star rating by the London-based Global Competition Review in its annual ranking of the World's top antitrust/competition authorities. The ...

Product sales in Global Specialty crossed 1/5th of overall sales," Sun Pharma Chairman and Managing Director Dilip Shanghvi said. "Our market share gain in India has been driven by industry-leading ...

Sun Pharmaceutical Industries Ltd. closed 11.11% below its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

10 lucky Fabulous readers will win a copy of this new novel in this week's book competition ... SE1 9GF. "The Sun", "Sun", "Sun Online" are registered trademarks or trade names of News Group ...

In contrast, Jefferies remained bullish, noting that Sun Pharma’s Q3 outperformance was driven by strong momentum in global specialty sales and mid-teens growth in its India business.

Our market share gain in India has been driven by industry-leading volume growth," said Dilip Shanghvi, Chairman and MD, Sun Pharma. For the India formulation business, sales increased by 14 per ...